Form 10-K Beam Therapeutics Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Beam Therapeutics Inc (BEAM) PT Raised to $44 at JPMorgan
February 27, 2024 12:03 PM ESTJPMorgan analyst Eric Joseph raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $44.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "Beam reported a 4Q23 earnings per share of $1.73 (FY23 loss per share of $1.72), while reiterating anticipated timelines regarding key data catalysts in 2024 for both BEAM-101 (SCD) and BEAM-302 (AATD) detailed at our Healthcare Conference. For BEAM-101 in SCD, having... More
